Avian Orthoavulavirus Type-1 as Vaccine Vector against Respiratory Viral Pathogens in Animal and Human

Abstract

Avian orthoavulaviruses type-1 (AOaV-1) have recently transitioned from animal vaccine vector to a bona fide vaccine delivery vehicle in human. Owing to induction of robust innate and adaptive immune responses in mucus membranes in both birds and mammals, AOaVs offer an attractive vaccine against respiratory pathogens. The unique features of AOaVs include over 50 years of safety profile, stable expression of foreign genes, high infectivity rates in avian and mammalian hosts, broad host spectrum, limited possibility of recombination and lack of pre-existing immunity in humans. Additionally, AOaVs vectors allow the production of economical and high quantities of vaccine antigen in chicken embryonated eggs and several GMP-grade mammalian cell lines. In this review, we describe the biology of AOaVs and define protocols to manipulate AOaVs genomes in effectively designing vaccine vectors. We highlighted the potential and established portfolio of AOaV-based vaccines for multiple respiratory and non-respiratory viruses of veterinary and medical importance. We comment on the limitations of AOaV-based vaccines and propose mitigations strategies. The exploitation of AOaVs vectors is expanding at an exciting pace; thus, we have limited the scope to their use as vaccines against viral pathogens in both animals and humans.

THEME: “Vaccines and Vaccine Adjuvants/Immunomodulators for Infectious Diseases”

“…Vilela et al discussed the characteristics of one such viral vector based on avian orthoavulavirus type-1 (AOaV-1), which is widely used in poultry and animals (sheep, dogs, cats, pigs, horses, and camels). Recent pre-clinical evidence supports the utilization of this vector for human viruses, including influenza and coronaviruses [ 16 ]. The COVID-19 era witnessed the popularization of viral vectors for human use with three adenoviral vector-based vaccines licensed for SARS-CoV-2.…”